Skip to main content
新赣江 logo

新赣江 — Investor Relations & Filings

Ticker · 920367 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 389 across all filing types
Latest filing 2024-01-21 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920367

About 新赣江

http://www.xgjyy.com/

Jiangxi Xinganjiang Pharmaceutical Co., Ltd. specializes in the research, development, production, and distribution of a diverse range of pharmaceutical products. The company's portfolio encompasses chemical active pharmaceutical ingredients (APIs), chemical drug preparations, and traditional Chinese medicine (TCM) formulations. Its core product offerings target therapeutic areas such as cardiovascular and cerebrovascular health, digestive system disorders, and nutritional supplementation. Key products include Ginkgo Biloba extract, Vitamin C, and various gastrointestinal medications. By maintaining an integrated value chain that spans from raw material synthesis to finished dosage forms, the company ensures quality control and supply chain efficiency. It focuses on delivering high-quality healthcare solutions through continuous innovation in pharmaceutical manufacturing and formulation technology.

Recent filings

Filing Released Lang Actions
关于更换持续督导保荐代表人的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the replacement of the continuous supervision sponsor representatives for the company. It details personnel changes related to the company's sponsor representatives and includes a brief biography of the new representative. There is no financial data, no report attached or referenced as being published, and no mention of voting results or meeting materials. This fits the category of a regulatory announcement about management or board-related changes but specifically about sponsor representatives, which is best classified under Regulatory Filings (RNS) as it does not fit the stricter Board/Management Information (MANG) category that usually covers directors or senior management changes. The document length is short and it is an announcement, not a report or presentation.
2024-01-21 Chinese
关于变更2023年年度审计机构质量控制复核人员的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the change of the quality control reviewer for the company's 2023 annual audit firm. It references the appointment of the audit firm for the 2023 fiscal year and details the personnel change within the audit firm. The document is short (1093 characters) and serves as a notification rather than containing the audit report itself or detailed financial data. It does not contain the audit report or financial statements but announces a change related to the audit process. Therefore, it fits best under 'Regulatory Filings' (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-12-24 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement by Jiangxi Xinganjiang Pharmaceutical Co., Ltd. regarding abnormal stock trading fluctuations over two recent trading days. It includes details about the investigation into the cause of the price movement, confirmation of no undisclosed material information, and a risk warning to investors. The document does not contain financial statements, management discussion, or detailed financial data. It is a regulatory announcement related to stock price behavior and compliance with stock exchange rules. Given the content and length (1347 characters), it fits the category of a Regulatory Filing (RNS) rather than a full financial report or other specific filing types.
2023-11-23 Chinese
关于公司收到政府上市补贴资金的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (434 characters) about the company receiving government listing subsidy funds. It includes a statement about accounting treatment to be confirmed by the annual audit but does not contain any financial statements or detailed financial data. It is an announcement of a financing-related event (government subsidy) but not a full capital or financing update report. Given the short length and nature of the content, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement about receipt of funds and accounting treatment, without detailed financial data or report content.
2023-11-05 Chinese
第二届监事会第十七次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Jiangxi Xinganjiang Pharmaceutical Co., Ltd. It details the meeting date, attendance, and the approval of two proposals: the 2023 third quarter report and the addition of routine related-party transactions for 2023. The document references the actual 2023 third quarter report published separately on the Beijing Stock Exchange information disclosure platform, indicating this document is not the report itself but a meeting resolution about it. The document length is short (1375 characters) and it serves as an official announcement of meeting decisions rather than containing substantive financial data or the full report. Therefore, it fits best under Regulatory Filings (RNS) as a formal announcement of supervisory board resolutions and related approvals, not the full interim report or other report types.
2023-10-29 Chinese
第二届董事会第二十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 26th meeting of the second board of directors of Jiangxi Xinganjiang Pharmaceutical Co., Ltd. It details the meeting's attendance, the approval of the 2023 third quarter report proposal, and approval of new related-party transactions for 2023. The document does not contain the actual financial statements or detailed financial data of the third quarter report but references that the full report was published separately on the Beijing Stock Exchange information disclosure platform. The document is primarily a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is short (1741 characters), and it is not the report itself but an announcement of board decisions including approval of reports and transactions. Therefore, the correct classification is MANG with high confidence.
2023-10-29 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.